ArticleHeart rhythm O22026
Comparative analysis of hemolysis incidence across 3 different pulsed field ablation systems.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Hemolysis Risk, Renal Function, and Safety Among Two Pulsed Field Ablation Systems: A Systematic Review and Meta-Analysis.Journal of arrhythmia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulsed field ablation (PFA) is associated with a risk of hemolysis; however, the differences among 3 single-shot PFA systems remain unclear. Objective: This study aimed to examine the differences in hemolysis among 3 PFA systems. Methods: We assessed changes in hemolytic, myocardial, and renal biomarkers at baseline and 24 hours after ablation in 131 patients with atrial fibrillation treated with 3 PFA systems (VARIPULSE, n = 26; PulseSelect, n = 62; FARAPULSE, n = 43), as well as in 23 patients undergoing radiofrequency ablation (control) and 8 patients without ablation (nonablation control). Results: Baseline characteristics were comparable across the groups. Haptoglobin levels decreased from 97.3 ± 52.1 to 49.9 ± 40.1 in the VARIPULSE group, 96.7 ± 41.9 to 53.5 ± 31.2 in the PulseSelect group, and 90.6 ± 43.8 to 27.3 ± 18.6 in the FARAPULSE group (all Conclusion: Intravascular hemolysis is a pertinent concern after PFA and is associated with the number of applications and body mass index, with potential differences across the 3 PFA systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.